Study finds heart disease drug promotes bone growth
New research has shown that phosphodiesterase (PDE) 3 inhibitors, used for treating thrombosis, heart diseases, and asthma, can promote bone growth by stimulating C-type natriuretic peptide (CNP) signalling.
Scientists have found that PDE3 inhibitors stimulate key signalling pathways that trigger Ca2+ influx into bone cells, promoting extracellular matrix production and bone growth.
This new therapeutic potential of PDE3 inhibitors was demonstrated using both in vivo and ex vivo approaches, suggesting that existing PDE3 inhibitors could be repositioned as therapies for skeletal disorders.
The team of researchers was led by Associate Professor Atsuhiko Ichimura from Ritsumeikan University, Professor Hiroshi Takeshima from Kyoto University, and graduate student Takaaki Kawabe from Kyoto University.
Dr Ichimura said: “We previously reported that CNP stimulates autonomic Ca2+ influx mediated by TRPM7 channels in growth plate chondrocytes to facilitate extracellular matrix (ECM) synthesis for bone growth. In this study, we attempted to stimulate CNP signalling using PDE inhibitors.”
When cilostazol, a representative PDE3 inhibitor, was added to the growth medium of metatarsal bone cultures, the researchers observed a significant increase in bone outgrowth when compared to control cultures.
To understand the in vivo effects of PDE3 inhibitors, three-week-old mice were treated with intraperitoneal injections of cilostazol for up to four weeks.
During the four weeks of treatment, the body length of the cilostazol-treated mice significantly increased, demonstrating that the application of PDE3 inhibitors may potentially stimulate body growth in young mice.
Immunochemical assessment of cyclic guanosine monophosphate (cGMP) in cilostazol-treated cultured bones revealed that the cGMP content in these cells was almost 1.7 times higher than that in the control cultures.
According to the researchers, the results suggest suggests that PDE3 inhibitors could be repurposed for treating conditions characterised by short stature, such as achondroplasia or idiopathic short stature.
Diana Spencer, Senior Digital Content Editor, DDW
